1. Latest News
  2. Submit Press Release

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2022

Nivolumab to Lead Lung Cancer Drug Market with Sales of $1.75 Billion by 2022

PRLog - July 16, 2013 - Bristol-Myers Squibb’s (BMS) nivolumab will overtake proven blockbuster competitors to dominate the Non-Small Cell Lung Cancer (NSCLC) treatment market following an expected 2015 launch, says research and consulting firm GlobalData.

According to the company’s latest analysis* nivolumab, a first-in-class immunotherapy, will become the overall NSCLC market sales leader by 2022, reaching revenue of $1.75 billion.

Covering the key markets of the US, UK, France, Germany, Italy, Spain and Japan, China and India, GlobalData’s new report expects BMS’s promising new immunotherapy to eventually outsell current marketed frontrunners Avastin and Tarceva over the forecast period. Leading pipeline drugs such as Afatinib, from Boehringer Ingelheim, and Eli Lilly’s necitumumab – with 2022 revenues forecast at $688m and $384m, respectively – will also be outperformed by nivolumab, states the report.

For further details, please click or add the below link to your browser:


Brooke Baker, PhD, oncology healthcare analyst with GlobalData, says: “NSCLC is the second most common cancer in both men and women, and patients who are diagnosed with the condition have an extremely poor prognosis, with five-year survival rates limited to approximately 2% in US patients diagnosed at stage four of the disease.

“However, nivolumab’s mechanism of action means it is able to exploit the body’s own immune system and initiate an anti-tumor immune response by targeting PD-1, a biomarker with high expression across many tumor types, therefore giving the drug the potential to be a blockbuster new NSCLC therapy.”

With BMS seeking to position the drug in the second line for all NSCLC patients, it could well fulfil two significant unmet needs within disease management: as a superior second-line therapy and as a treatment for squamous patients. Expected entry of nivolumab in the first-line setting in 2019 will cement the leading position of BMS’s strong asset, states the report.

Considering these advantages, GlobalData believes that nivolumab will become a key driver behind the growth of the global NSCLC market, which is expecting to rise at a Compound Annual Growth Rate (CAGR) of 3.3%, from $5.7 billion in 2012 to $7.9 billion in 2022.

“This level of growth will also result from an increasing number of NSCLC incident cases in the majority of the markets covered by the report, especially in Japan and the emerging markets of China and India,” says Baker.



*PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2022

This forecast provides an overview of Non-Small Cell Lung Cancer, and includes an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.


GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insightthat helps our clients to achieve growth and increase business value.

Visit our report store: http://store.globaldata.com/

For more details contact:pressreleases@globaldata.com

North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782

--- End ---

Click to Share

Contact Email:
***@globaldata.com Email Verified
Location:London, Greater - United Kingdom
Tags:PharmaPoint, lung cancer, nsclc, globaldata
Last Updated:Jul 16, 2013
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

Like PRLog?
Click to Share